VIGL (Vigil Neuroscience) EPS (Basic) : $-2.05 (TTM As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is Vigil Neuroscience EPS (Basic)?

Vigil Neuroscience's basic earnings per share (Basic EPS) for the three months ended in Mar. 2025 was $-0.49. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2025 was $-2.05.

Vigil Neuroscience's EPS (Diluted) for the three months ended in Mar. 2025 was $-0.49. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-2.05.

Vigil Neuroscience's EPS without NRI for the three months ended in Mar. 2025 was $-0.49. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2025 was -2.05.

During the past 3 years, the average EPS without NRI Growth Rate was -10.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, Vigil Neuroscience's highest 3-Year average EPS without NRI Growth Rate was -10.60% per year. The lowest was -10.60% per year. And the median was -10.60% per year.

Vigil Neuroscience EPS (Basic) Historical Data

The historical data trend for Vigil Neuroscience's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vigil Neuroscience EPS (Basic) Chart

Vigil Neuroscience Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

-1.53

-2.16

-2.13

-2.07

Vigil Neuroscience Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EPS (Basic)	Get a 7-Day Free Trial														-0.50	-0.52	-0.47	-0.57	-0.49

Vigil Neuroscience EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Vigil Neuroscience's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-84.256	-	0)	/	40.668
	=	-2.07

Vigil Neuroscience's Basic EPS for the quarter that ended in Mar. 2025 is calculated as

Basic EPS (Q: Mar. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-22.413	-	0)	/	46.068
	=	-0.49

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.05

Vigil Neuroscience (NAS:VIGL) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Vigil Neuroscience EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Vigil Neuroscience's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Vigil Neuroscience Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vigil Neuroscience Inc (NAS:VIGL) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Forge Road, Suite 700, Watertown, MA, USA, 02472

Website

https://www.vigilneuro.com

Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.

Executives

Ivana Magovcevic-liebisch	director, officer: President and CEO	300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Budd Haeberlein Samantha L.	director	VIGIL NEUROSCIENCE, INC., 100 FORGE ROAD, SUITE 700, WATERTOWN MA 02472
Christopher Silber	officer: Chief Medical Officer	C/O VIGIL NEUROSCIENCE, INC., 100 FORGE ROAD, SUITE 700, WATERTOWN MA 02472
Gray David L. F.	officer: Chief Science Officer	VIGIL NEUROSCIENCE, INC., 100 FORGE ROAD, SUITE 700, WATERTOWN MA 02472
Spyridon Papapetropoulos	officer: Chief Medical Officer	C/O ADAMAS PHARMACEUTICALS, INC., 1900 POWELL ST., SUITE 1000, EMERYVILLE CA 94608
Suzanne Louise Bruhn	director	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Clay Thorp	director	C/O HATTERAS VENTURE PARTNERS III, LP, 280 S. MANGUM ST., SUITE 350, DURHAM NC 27701
Evan Thackaberry	officer: SVP, Head of Early Development	VIGIL NEUROSCIENCE, INC., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Jennifer Lynn Ziolkowski	officer: Chief Financial Officer	C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Christopher Verni	officer: General Counsel	VIGIL NEUROSCIENCE, INC., 1 BROADWAY, 7TH FLOOR, SUITE 07-300, CAMBRIDGE MA 02142
Mary Thistle	director	C/O VIACELL, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
Atlas Venture Fund Xii, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Bruce Booth	director	890 WINTER STREET, SUITE 320, WALTHAM MA 02451
Stefan Vitorovic	director	C/O PRAXIS PRECISION MEDICINES, INC., ONE BROADWAY, 16TH FLOOR, CAMBRIDGE MA 02142
Northpond Ventures Gp, Llc	10 percent owner	7500 OLD GEORGETOWN ROAD, SUITE 850, BETHESDA MD 20814